Bio-Rad Laboratories, Inc. (BIO) SEC Filings & Earnings Calls

Middle East conflict disruption

“Additionally, the recent escalation of regional conflicts in the Middle East has adversely affected demand and logistics in the EMEA region, particularly within our Clinical Diagnostics segment.” · word for word

China market uncertainty

“The market in China, which represents a mid-single digit percentage of our year-to-date 2026 consolidated net sales, remains uncertain as a result of these factors.” · word for word

Government funding reductions

“Reduced government spending, along with ongoing challenges in the biopharma market and among small biotech companies, continues to negatively impact our business.” · word for word

Tariff and trade policy volatility

“We also continue to analyze the impacts on our business as recent events unfold regarding tariffs imposed by the United States... could lead to higher prices, inflation and possibly a recession.” · word for word

Sartorius AG investment volatility

“Changes in the market value of our position in Sartorius AG will continue to materially impact our condensed consolidated statements of income (loss) and other financial statements.” · word for word

Life Science segment continues to decline due to academic research market softness

“Life Science segment net sales decreased 4.1% (5.1% currency-neutral) driven by ongoing challenges in the academic research market”

Restructuring execution risk with $80-90M charges and headcount reductions

“Restructuring plan includes elimination of positions, consolidation of functions, and facility closures; subject to local consultative processes”

Flat revenue overall with operating cash flow decline

“Net cash from operations $98.7M vs $116.5M; free cash flow $66.7M vs $70.8M”

Middle East conflict disruption

“Additionally, the recent escalation of regional conflicts in the Middle East has adversely affected demand and logistics in the EMEA region, particularly within our Clinical Diagnostics segment.” · word for word

China market uncertainty

“The market in China, which represents a mid-single digit percentage of our year-to-date 2026 consolidated net sales, remains uncertain as a result of these factors.” · word for word

Government funding reductions

“Reduced government spending, along with ongoing challenges in the biopharma market and among small biotech companies, continues to negatively impact our business.” · word for word

Tariff and trade policy volatility

“We also continue to analyze the impacts on our business as recent events unfold regarding tariffs imposed by the United States... could lead to higher prices, inflation and possibly a recession.” · word for word

Sartorius AG investment volatility

“Changes in the market value of our position in Sartorius AG will continue to materially impact our condensed consolidated statements of income (loss) and other financial statements.” · word for word

Guidance cut signals weakening demand and margin pressure; academic research and Middle East conflicts are key headwinds.

“Full-year revenue guidance lowered from +0.5-1.5% to -3.0% to +0.5%; operating margin guidance cut from 12-12.5% to 10-12%.”

Currency-neutral revenue decline of 4.2% indicates underlying weakness beyond FX translation.

“Currency-neutral sales decreased 4.2% compared to same period in 2025.”

GAAP net loss of $527M from investment mark-to-market introduces earnings volatility.

“Net loss of $527.1 million due to change in fair market value of Sartorius AG investment.”

Potential dilution from increased share reserve, though modest relative to total shares outstanding.

“increase the shares of common stock reserved for issuance under the Plan by 335,000 shares” · word for word

Concentrated voting control by Schwartz family

“A significant majority of our voting stock is held by the Schwartz family, which could lead to conflicts of interest.”

Debt covenant restrictions

“Our current and future debt and related covenants may restrict our future operations.”

Healthcare regulatory compliance

“We are subject to healthcare laws and regulations and could face substantial penalties if we are unable to fully comply with such laws.”

Geopolitical and macroeconomic uncertainty

“Current global economic and geopolitical conditions remain uncertain, and we rely on the support of many governments for both research and healthcare.”

China market uncertainty

“the market in China, which represents a mid-single digit percentage of our 2025 consolidated net sales, remains uncertain as a result of these factors.”

Bio-Rad's investment in Sartorius AG is subject to market and operational risks of Sartorius, but no new risk is disclosed.

“Routine disclosure of investee financials; no material change to Bio-Rad's risk profile.”

IPR&D impairment risk

“In December 2025, we impaired the IPR&D asset associated with our 2021 acquisition of Dropworks, Inc. (“Dropworks”) amounting to $81.7 million ... In December 2025, we discontinued development of the IPR&D asset associated with our 2022 acquisition of Curiosity Diagnostics, Sp. Z. o. o. ("Curiosity") and recorded an impairment charge of $127.7 million.” · word for word

Gross margin pressure

“Consolidated gross margin was 51.9% for the year ended December 31, 2025 compared to 53.7% for the year ended December 31, 2024.” · word for word

Life Science segment demand headwind

“The Life Science segment sales for the year ended December 31, 2025 were $1.02 billion, a decrease of 0.7% compared to the year ended December 31, 2024. On a currency neutral basis, sales decreased 1.3% compared to the year ended December 31, 2024, driven by the constrained academic research and biotech funding environment.” · word for word

China market headwind

“the market in China, which represents a mid-single digit percentage of our 2025 consolidated net sales, remains uncertain as a result of these factors.” · word for word

Foreign exchange exposure

“The international sales are largely denominated in local currencies such as the Euro, Swiss Franc, Japanese Yen, Chinese Yuan and British Sterling. As a result, our consolidated net sales expressed in dollars benefit when the U.S. dollar weakens and suffer when the dollar strengthens.” · word for word

Significant operating loss in Q4, gross margin compression, and challenging end-market conditions (geopolitical uncertainty, academic funding pressure).

“Q4 operating loss of $118.9M; gross margin decline; CEO commentary on challenging year.”

Biotech funding headwinds persist

“Reduced government spending, along with ongoing challenges in the biopharma market and among small biotech companies, continues to negatively impact our business.” · word for word

China reimbursement cuts

“The currency neutral sales decrease was primarily driven by the lower reimbursement rates for diabetes testing in China.” · word for word

Sartorius AG valuation volatility

“Changes in the market value of our position in Sartorius AG will continue to materially impact our consolidated statements of income (loss) and other financial statements.” · word for word

Academic research and biotech funding constraints continue to pressure Life Science instrument demand.

“CEO: 'ongoing challenges in academic research and biotech funding, and the resulting reduced demand for instruments.'”

Lower reimbursement rates for diabetes testing in China impacting Clinical Diagnostics segment.

“Currency-neutral sales decrease driven by lower reimbursement rates for diabetes testing in China.”

GAAP net loss due to Sartorius AG investment fair value change; volatility in equity securities impacts reported earnings.

“Change in fair market value of Sartorius AG investment contributed to net loss.”